A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

NCT03972150 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BI 836880
DRUG: BI 754091

Sponsor

Boehringer Ingelheim